title: Susceptibility of multiresistant serotype 012 Pseudomonas aeruginosa to fosfomycin in combination with other antibiotics.
abstract: Serotype 012 represented 15% of 244 isolates of Pseudomonas aeruginosa isolated in the hospital over a 2 year-period and most isolates of this serotype were resistant to multiple antibiotics. Combination experiments showed that fosfomycin and amikacin together were active against 92% of 012 isolates. It is recommended that serotyping be used systematically to identify 012 strains rapidly and fosfomycin/amikacin be considered as a presumptive antipseudomonal therapy in 012 infections.
authors: Laboratoire de Biologie Clinique, CHG, Rodez, France.
authors: J
authors: J
authors: Watine
authors: C
authors: C
authors: Bourrel
authors: B
authors: B
authors: Dubourdieu
authors: J L
authors: JL
authors: Gineston
authors: P
authors: P
authors: Bories
authors: M
authors: M
authors: Durand
authors: A
authors: A
authors: Marre
authors: F
authors: F
authors: Formosa
authors: M P
authors: MP
authors: Brunel
authors: J
authors: J
authors: Palliez
mesh_terms: D042462:4-Quinolones; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000494:pharmacology; D005578:Fosfomycin / Q000494:pharmacology*; D066298:In Vitro Techniques; D007769:Lactams; D011550:Pseudomonas aeruginosa / Q000187:drug effects*
chemical_list: D042462:4-Quinolones; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D007769:Lactams; D005578:Fosfomycin